WX ATU is a leading China-based CDMO dedicated exclusively to Cell and Gene Therapy (CGT), providing integrated end-to-end solutions from early development to commercial manufacturing.
As China’s first CGT CDMO inspected by both NMPA and the U.S. FDA, WX ATU combines regulatory credibility, manufacturing excellence, and execution speed to help innovators accelerate programs toward IND, BLA, and commercialization.
Our platform covers plasmid DNA, mRNA, viral vectors (LVV, AAV, RVV), and cell therapies (CAR-T, TCR-T, CAR-NK), supported by GMP-compliant facilities, robust quality systems, and scalable manufacturing infrastructure designed for global programs.
With 150+ global clients served, 30+ IND/BLA programs supported, 600+ GMP lots delivered, and commercial manufacturing experience since 2023, WX ATU has become a trusted partner for biotech innovators and multinational pharmaceutical companies worldwide.
We believe CMC is not only execution — it is strategy. Through science-driven development, proactive regulatory planning, and reliable GMP delivery, WX ATU enables breakthrough therapies to reach patients faster.